Introduction

This article will explore how Erdheim-Chester disease (ECD) affects the heart, blood vessels and kidneys. It will make key concepts easy to understand while maintaining scientific accuracy. Through current medical research, it will walk you through the main cardiovascular and perirenal symptoms of ECD.

What is Erdheim-Chester disease (ECD)?

Erdheim-Chester Disease (ECD) is a rare disease in which specific immune cells accumulate in various tissues, leading to damage and scarring. The symptoms can differ greatly because it can impact so many organs. While some may experience minor issues, others may experience severe, potentially fatal complications.⁹

The most prevalent symptom of ECD is bone pain, particularly in the legs. In fact, scans of nearly all patients reveal some kind of bone involvement. However, the brain, heart, kidneys, and other organs can also be impacted by ECD. People are frequently misdiagnosed at first because of the wide range of potential symptoms, which makes diagnosis difficult.⁹

Although rare occurrences have been documented in children, ECD often manifests in individuals between the ages of 50 and 60. Early detection is essential for guiding treatment and improving therapeutic outcomes, despite the illness being extremely rare and often overlooked.¹

Pathogenesis and epidemiology of ECD.

ECD arises when specific immune cells, known as histiocytes, begin acting abnormally. They accumulate in various parts of the body rather than disappearing as they’re supposed to. Inflammation and scarring caused by this excess accumulation over time can harm organs such as the brain, kidneys, heart, and bones.^2,3

The majority of patients diagnosed with this ailment are men, typically in their middle years, though it can occur at any time from adolescence to old age. Childhood cases are extremely rare, and when they do occur, cardiac effects are rarely present.³ 

In the past, people frequently had to wait years or even decades to receive the correct diagnosis. However, now, ECD is usually detected earlier, mainly because patients and physicians are more aware of the illness and its warning signs.³

The prevalence of ECD is unknown because there is no standardised method to monitor cases. What we do know is that it primarily affects adults, typically in their forties and seventies. It is extremely uncommon and typically has no effect on the heart in children. Rather, the illness may initially manifest in a juvenile brain or neurological system. Similar to adults, people assigned male at birth (AMAB) are more likely than people assigned female at birth (AFAB) to develop ECD.^2,3

Cardiovascular manifestations in ECD

Erdheim-Chester disease (ECD) frequently affects the heart and blood vessels; in as many as seven out of ten cases, some degree of cardiac pathology is seen. Some people may not have any symptoms at all, while others may experience severe, sometimes fatal issues.⁴

One hallmark is periaortic fibrosis, frequently referred to as a "coated aorta." This occurs when the body's major artery, the aorta, becomes encircled by a thick layer of tissue. While the aorta often does not expand or rupture as in other disorders, it might narrow and squeeze surrounding arteries.^5,10

When this narrowing occurs in the kidney arteries, it can result in high blood pressure that is extremely difficult to manage. If this affects arteries in the intestines or legs, claudication (pain in the legs when walking) might occur. Similarly, mesenteric ischaemia, which causes stomach pain after eating, is another knock-on effect.⁵

Additionally, the heart itself may be affected. Some individuals experience pericardial effusion, an accumulation of excess fluid in the protective sac around the heart. Pericarditis, or, in rare instances, cardiac tamponade (a severe condition in which the heart is squeezed and unable to pump blood effectively), can also occur. As well as these conditions, heart attacks may result from the narrowing of the coronary arteries. ECD cells can occasionally invade the heart's own tissue, causing arrhythmias or other heart failure symptoms.⁵

Large veinsthat carry blood back to the heart can also be damaged. In rare cases, this has resulted in a disease known as portal hypertension, in which blood pressure rises in the liver's veins. Given that leg bone pain is so prevalent in ECD, physicians must exercise caution when patients report leg pain; inadequate blood flow from arterial narrowing can be mistaken for bone pain. More examples of involvement of the heart and blood vessels are being identified, but physicians are still learninghow these issues progress over time and how well they respond to treatment. ^4,5

Retroperitoneal and perirenal manifestations in ECD

Another commonly affected area in Erdheim-Chester disease (ECD) is the retroperitoneal space, which is the region behind the abdominal organs. Doctors frequently notice alterations in nearby tissues, such as the kidneys, adrenal glands, and ureters (the tubes that carry urine to the bladder), on scans, along with a "coated aorta"—thick tissue around the main artery.⁶

The majority of individuals with retroperitoneal involvement are asymptomatic. When symptoms do appear, they may include abdominal pain, trouble urinating, or occasionally enlarged kidneys that are noticeable during a physical examination.⁶

A common CT scan finding is a "hairy kidney," which occurs when abnormal tissue accumulates around the kidneys, giving them a fuzzy appearance. Although surgery has been employed in rare instances to reduce the strain this can cause, in severe circumstances, the tissue can push on the kidneys and result in renal failure.⁶

The disease can also obstruct the ureters, causing hydronephrosis (kidney enlargement due to retained urine), or it might spread to the arteries that supply the kidneys. The kidneys receive less blood if the renal arteries narrow, which can lead to difficult-to-control high blood pressure.⁶

The adrenal glands, located above the kidneys, are frequently affected as well, typically on both sides. In rare instances, adrenal insufficiency—a condition in which these glands are unable to generate enough hormones to meet the body's needs—can result from this, even though it is frequently overlooked.⁶

Diagnosis and imaging

Erdheim-Chester disease (ECD) is diagnosed using a combination of tests, as no single test is sufficient on its own. Blood tests, hormone checks, and imaging scans are typically used by doctors to look for typical disease symptoms.⁷ 

Typical scan results include:⁷

• Bone changes in the legs (especially the tibia and femur)
• Kidney involvement (“hairy kidney”)
• Thick tissue around the aorta (“coated aorta”)
• Heart masses, such as a right atrial pseudotumor

A biopsy, which involves extracting a tissue sample, remains necessary to confirm the diagnosis, regardless of whether imaging results strongly suggest ECD. A biopsy is frequently performed from lesions in the skin, bone, or kidney, or from the region that has the highest level of activity on PET scans.⁷ 

The tissue sample is examined under a microscope and analysedfor genetic alterations that could guide treatment. In some cases, if the genetic tests and imaging results are very characteristic of ECD, a diagnosis can be made even if the tissue lacks the “classic” cell pattern. ⁷

Treatment approaches for ECD.

The primary treatment for ECD is interferon-alpha, which has been shown to increase survival and is often administered over an extended period. The newer PEGylated (longer-lasting) versions are more tolerable, although common adverse effects include fatigue and malaise. Regular imaging scans are necessary to monitor progress because treatment response is sometimes not immediate.⁸

Other choices for patients with less severe presentation of the condition(without heart or brain involvement), or those unable to take interferon include:⁸

• Anakinra
• Infliximab
• Sirolimus combined with steroids

The biggest advancement has been the use of targeted therapies, which fight genetic alterations present in many ECD patients:⁸

• BRAF inhibitors (vemurafenib and dabrafenib) are highly successful, particularly in patients with the BRAFV600E mutation. Vemurafenib may have more adverse effects than dabrafenib
• MEK inhibitors (cobimetinib) are beneficial even in patients without the BRAF mutation

Targeted treatments have produced robust and long-lasting effects, particularly in severe heart or brain disorders. However, they are often used only for patients with more severe conditions due to the risk of adverse effects. ⁸

Summary

Erdheim-Chester Disease (ECD) is an extremely rare condition in which particular immune cells accumulate in the body, causing scarring and damage. Though it can occur at any age, it often affects adults between the ages of 40 and 70 and is more common in those AMAB. Though the disease can also damage the heart, kidneys, brain, lungs, and skin, leg bone pain is the most frequent complaint. It is difficult to identify because the symptoms vary so significantly.

In many cases, the heart and blood vessels are involved. One of the primary issues is a "coated aorta," in which the biggest artery in the body is surrounded by thick tissue. Leg pain when walking, stomach ache after eating, and high blood pressure can all result from this narrowing of blood vessels. In certain situations, the heart may develop fluid surrounding it, beat irregularly, or develop heart failure.

The kidneys can also be impacted. They might be surrounded by abnormal tissue, which can cause a "hairy kidney" appearance on scans. The kidneys and adrenal glands may be affected, and urine flow may be blocked.

A biopsy, blood tests, and scans are needed for the diagnosis. Interferon-alpha is typically the first-line treatment, but more recent targeted medications, such as BRAF or MEK inhibitors, are now improving outcomes, particularly in more severe patients.